IR Stock Analysis: Ingersoll Rand | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 31.870m USD | 12M Return: 9.9% | US45687V1061 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 356M
EPS Trend: 84.7%
Qual. Beats: 1
Rev. Trend: 99.2%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 9.5 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Ingersoll Rand Inc. (NYSE: IR) is a global provider of mission-critical air, fluid, clean energy, and medical technologies, operating through two main segments: Industrial Technologies and Services, and Precision and Science Technologies. The Industrial segment focuses on compressors, vacuum and blower products, fluid transfer equipment, loading systems, and power tools, while the Precision and Science Technologies segment manufactures pumps, gas boosters, hydrogen compression systems, and liquid handling solutions for medical, laboratory, industrial, water and wastewater, chemical processing, clean energy, food and beverage, and agricultural applications.
The company sells its products under a wide portfolio of well-established brands, including Gardner Denver, Nash, CompAir, Elmo Rietschle, ARO, Haskel, Milton Roy, Thomas, Welch, and Seepex, among others. Distribution is conducted through a combination of direct sales representatives and independent distributors, and the company maintains a strategic alliance with Garrett Motion. As a Large Cap industrial machinery company headquartered in Davidson, North Carolina, Ingersoll Rand was founded in 1859 and was formerly known as Gardner Denver Holdings, Inc. before adopting its current name in March 2020.
- orders track global manufacturing PMI cycle
- Aftermarket services revenue mix expands operating margins
- Bolt-on acquisitions accelerate growth in precision fluid handling
| Net Income: 1.38b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 1.28 > 1.0 |
| NWC/Revenue: 23.86% < 20% (prev 30.00%; Δ -6.14% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.64b > Net Income 1.38b |
| Net Debt (3.47b) to EBITDA (2.42b): 1.44 < 3 |
| Current Ratio: 1.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (388.1m) vs 12m ago -3.10% < -2% |
| Gross Margin: 38.28% > 18% (prev 43.72%; Δ -5.44% > 0.5%) |
| Asset Turnover: 43.76% > 50% (prev 41.00%; Δ 2.76% > 0%) |
| Interest Coverage Ratio: 7.34 > 6 (EBIT TTM 1.87b / Interest Expense TTM 254.7m) |
| A: 0.10 (Total Current Assets 4.71b - Total Current Liabilities 2.79b) / Total Assets 18.6b |
| B: 0.22 (Retained Earnings 4.15b / Total Assets 18.6b) |
| C: 0.10 (EBIT TTM 1.87b / Avg Total Assets 18.4b) |
| D: 1.31 (Book Value of Equity 10.5b / Total Liabilities 8.05b) |
| Altman-Z'' = 3.46 = A |
| DSRI: 0.99 (Receivables 1.53b/1.43b, Revenue 8.05b/7.46b) |
| GMI: 1.14 (GM 43.72% / 38.28%) |
| AQI: 0.97 (AQ_t 0.70 / AQ_t-1 0.72) |
| SGI: 1.08 (Revenue 8.05b / 7.46b) |
| TATA: -0.01 (NI 1.38b - CFO 1.64b) / TA 18.6b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of November 13, 2026, the stock is trading at USD 85.31 with a total of 4,421,842 shares traded. Over the past week, the price has changed by +4.25%, over one month by +7.89%, over three months by +0.70% and over the past year by +9.91%.
Current recommended Stop Loss: 78.70 (which is 7.7% or 2.4 ATR below the current price).
Ingersoll Rand has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy IR.
- StrongBuy: 7
- Buy: 0
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 94.9 | 11.3% |
P/E Trailing = 23.5099
P/E Forward = 20.5761
P/S = 3.9579
P/B = 3.0344
P/EG = 0.6686
Revenue TTM = 8.05b USD
EBIT TTM = 1.87b USD
EBITDA TTM = 2.42b USD
Long Term Debt = 4.06b USD (from longTermDebt, last quarter)
Short Term Debt = 700.2m USD (from shortTermDebt, last quarter)
Debt = 4.82b USD (from shortLongTermDebtTotal, last quarter) + Leases 80.0m
Net Debt = 3.47b USD (calculated: Debt 4.82b - CCE 1.34b)
Enterprise Value = 35.3b USD (31.9b + Debt 4.82b - CCE 1.34b)
Interest Coverage Ratio = 7.34 (Ebit TTM 1.87b / Interest Expense TTM 254.7m)
EV/FCF = 23.30x (Enterprise Value 35.3b / FCF TTM 1.52b)
FCF Yield = 4.29% (FCF TTM 1.52b / Enterprise Value 35.3b)
FCF Margin = 18.84% (FCF TTM 1.52b / Revenue TTM 8.05b)
Net Margin = 17.20% (Net Income TTM 1.38b / Revenue TTM 8.05b)
Gross Margin = 38.28% ((Revenue TTM 8.05b - Cost of Revenue TTM 4.97b) / Revenue TTM)
Gross Margin QoQ = 44.76% (prev 42.10%)
Tobins Q-Ratio = 1.90 (Enterprise Value 35.3b / Total Assets 18.6b)
Interest Expense / Debt = 5.29% (Interest Expense 254.7m / Debt 4.82b)
Taxrate = 13.92% (225.1m / 1.62b)
NOPAT = 1.61b (EBIT 1.87b * (1 - 13.92%))
Current Ratio = 1.69 (Total Current Assets 4.71b / Total Current Liabilities 2.79b)
Debt / Equity = 0.46 (Debt 4.82b / totalStockholderEquity, last quarter 10.5b)
Debt / EBITDA = 1.44 (Net Debt 3.47b / EBITDA 2.42b)
Debt / FCF = 2.29 (Net Debt 3.47b / FCF TTM 1.52b)
Total Stockholder Equity = 10.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.53% (Net Income 1.38b / Total Assets 18.6b)
RoE = 13.53% (Net Income TTM 1.38b / Total Stockholder Equity 10.2b)
RoCE = 13.08% (EBIT 1.87b / Capital Employed (Equity 10.2b + L.T.Debt 4.06b))
RoIC = 9.98% (NOPAT 1.61b / Invested Capital 16.1b)
WACC = 8.51% (E(31.9b)/V(36.7b) * Re(9.11%) + D(4.82b)/V(36.7b) * Rd(5.29%) * (1-Tc(0.14)))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.25 | Cagr: -2.13%
[DCF] Terminal Value 77.45% ; FCFF base≈1.41b ; Y1≈1.62b ; Y5≈2.38b
[DCF] Fair Price = 81.60 (EV 34.8b - Net Debt 3.47b = Equity 31.3b / Shares 384.0m; r=8.51% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.74 | EPS CAGR: 4.72% | SUE: 4.0 | # QB: 1
Revenue Correlation: 99.18 | Revenue CAGR: 5.93% | SUE: 0.34 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.83 | Chg30d=+1.41% | Revisions=+40% | Analysts=8
EPS current Year (2026-12-31): EPS=3.65 | Chg30d=+2.76% | Revisions=+50% | GrowthEPS=+9.3% | GrowthRev=+6.3%
EPS next Year (2027-12-31): EPS=3.95 | Chg30d=+0.85% | Revisions=+17% | GrowthEPS=+8.2% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +55% (up=7, down=1)